SARS-CoV-2 Molecular Structure: From Pandemic Analysis to Therapeutic Targets

SARS-CoV-2: From Molecular Structure to Global Pandemic Analysis

SARS-CoV-2 is a β-coronavirus with spherical virions 80–120 nm in diameter, their surfaces densely covered with spike (S) protein. The S protein contains S1, which binds the ACE2 receptor with a KD of approximately 15 nM, and S2, which mediates membrane fusion. Its 29.9 kb RNA genome encodes 29 proteins, and the S gene varies markedly, including a unique Furin cleavage site (PRRA). The macrodomain of nsp3 hydrolyzes ADP-ribose and suppresses host immune responses.

Virion Structure and Genome Features

As a new member of the β-coronavirus genus, SARS-CoV-2 shows a spherical or pleomorphic virion about 80–120 nm in diameter, surrounded by a lipid bilayer envelope. The surface carries spike (S) protein trimers 9–12 nm long at a density of about 24–40 per particle, forming the characteristic crown structure.

SARS-CoV-2 virion structure and genome organization

Cryo-electron microscopy reveals that the S protein consists of two functional subunits, S1 and S2. The receptor-binding domain (RBD) of S1 binds the host cell angiotensin-converting enzyme 2 (ACE2) receptor with high affinity (KD ≈ 15 nM). S2 then mediates fusion of the viral and cellular membranes.

In terms of genome, SARS-CoV-2 carries about 29.9 kb of positive-sense single-stranded RNA, one of the largest genomes among known RNA viruses. It contains 14 open reading frames (ORFs) that encode at least 29 proteins. Compared with other coronaviruses, its genome is highly conserved in the nucleocapsid (N) and membrane (M) protein regions, but shows significant variation in the S gene. Insertion of a Furin protease cleavage site (PRRA sequence) enhances viral infectivity. The macrodomain in non-structural protein nsp3 has ADP-ribose hydrolase activity and may interfere with host innate immune responses.

Viral Entry and Replication Cycle

SARS-CoV-2 infection begins with binding of the S protein to the host ACE2 receptor. This process is significantly regulated by the cell surface transmembrane serine protease 2 (TMPRSS2). TMPRSS2 cleaves the S1/S2 site of the S protein with about 30% efficiency, exposing the fusion peptide and promoting fusion of the viral envelope with the cell membrane.

Single-virus particle tracking shows that binding to internalization takes an average of 15–30 minutes. Temperature-dependent experiments indicate that this process is most efficient at 37°C. After entering the cell, viral RNA directly serves as mRNA to translate the replicase polyproteins pp1a and pp1ab. These polyproteins are processed by the virus-encoded main protease (3CLpro) and papain-like protease (PLpro) into 16 non-structural proteins, forming the replication-transcription complex (RTC).

Viral RNA synthesis shows complex dynamics. Negative-strand RNA templates begin large-scale synthesis 4–6 hours after infection, while positive-strand genomic RNA and subgenomic mRNA peak at 8–12 hours. The virus uses a discontinuous transcription mechanism to produce 9 subgenomic mRNAs, each containing a common 5' leader sequence and 3' terminal sequence. Live-cell imaging shows that a single infected cell produces an average of about 1,000 virions, with release occurring mainly 12–24 hours after infection.

Immune Evasion Mechanisms and Host Response

SARS-CoV-2 has evolved multiple strategies to evade host immune surveillance. The most prominent is suppression of the type I interferon (IFN) response. The viral protein Orf6 binds the nuclear pore complex and inhibits STAT1/2 nuclear translocation, reducing interferon-stimulated gene (ISG) expression by more than 80%.

The N protein sequesters double-stranded RNA to prevent RIG-I/MDA5 recognition. Meanwhile, nsp16-mediated 2'-O-methylation of the RNA cap allows viral RNA to evade recognition by the MxA protein. Together, these mechanisms cause a delay in the interferon response during early infection (24–48 hours), creating a time window for viral replication.

The host adaptive immune response shows high heterogeneity. Neutralizing antibodies mainly target the RBD and N-terminal domain (NTD) of the S protein, but epitope recognition patterns differ significantly among individuals. Serological analysis of recovered patients shows that about 70% produce RBD-targeting neutralizing antibodies. Titers range from 1:100 to 1:5,000 with a half-life of about 35–60 days.

For T cell responses, CD4+ T cells mainly recognize the fusion peptide region of the S protein and the C-terminus of the N protein. CD8+ T cells tend to target non-structural proteins such as nsp3 and nsp12. Multiparameter flow analysis reveals that severe patients often show T cell exhaustion features such as PD-1 and TIM-3 upregulation. Mild patients maintain multifunctional T cell responses with coordinated production of IFN-γ, IL-2, and TNF-α.

About 20–50% of unexposed individuals have T cells that recognize SARS-CoV-2, possibly derived from prior infection with common cold coronaviruses such as HCoV-OC43. These cross-reactive T cells mainly target conserved regions of replicase proteins. Antibody cross-reactivity is weaker. Neutralizing antibodies against SARS-CoV-1 have only limited capacity against SARS-CoV-2, with titers reduced 10–50 fold.

Evolutionary Dynamics of Variants

Since the outbreak, SARS-CoV-2 has continuously evolved, producing several variants of concern (VOC). The N501Y mutation carried by the Alpha variant (B.1.1.7) increases RBD affinity for ACE2 by 4–6 fold. The D614G mutation enhances infectivity by stabilizing the open conformation of the S protein.

The E484K and K417N mutations of the Beta variant (B.1.351) confer significant antibody escape, increasing resistance to convalescent serum neutralization by 10–30 fold. The L452R and P681R mutations of the Delta variant (B.1.617.2) enhance membrane fusion efficiency. Viral loads reach 1,000 times those of early strains, with an incubation period shortened to about 4 days.

The Omicron variant (B.1.1.529) represents the most significant immune escape phenotype to date. Its S protein carries more than 30 mutations, including 15 RBD mutations, increasing resistance to neutralization by vaccinated sera 20–40 fold. Cryo-electron microscopy shows that the Omicron RBD adopts a more compact conformation, shielding or altering the epitopes of many neutralizing antibodies. Omicron replicates more efficiently in the upper respiratory tract while showing reduced replication capacity in lung tissue, explaining its high transmissibility but lower pathogenicity. Recombinant variants such as XBB further integrate multiple mutations and show stronger resistance to monoclonal antibodies.

Evolution and Application of Diagnostic Technology

Nucleic acid testing remains the gold standard for confirming COVID-19. Real-time RT-PCR designs primers and probes against multiple targets such as ORF1ab, N, and E genes, with a detection limit of 10–100 copies/mL. Sample type comparison shows that nasopharyngeal swab positivity is about 70–80%, while sputum can reach over 90%.

Antigen testing is widely used as a rapid screening tool. Lateral flow immunochromatographic strips mainly target the N protein, reaching 90% sensitivity when viral load exceeds 10^5 copies/mL. Sensitivity drops sharply to 30% below this threshold. Antigen testing performs best 1–3 days after symptom onset, when viral shedding peaks.

Vaccine Development and Immune Protection

Vaccine protection against variants shows a gradient decline. Against the Delta strain, mRNA vaccine efficacy against infection dropped from the original 95% to 80%, but protection against hospitalization remained above 90%. The emergence of Omicron led to greater breakthrough infection risk, with efficacy against infection dropping to 30–50%. Booster vaccination restored protection against severe disease to 70–80%. Heterologous boosting strategies show broader immune responses, with neutralizing antibody titers 2–3 times higher than homologous regimens.

Public Health Response and Social Impact

Global surveillance network construction has made significant progress. Genome sequencing capacity has increased from several thousand per week early in the pandemic to the current scale of millions, shortening variant detection time from months to weeks. Wastewater surveillance can predict case surges 1–2 weeks in advance, with sensitivity of 1 infection per 100,000 people.

Related Products

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research by delivering high-quality recombinant proteins, antibodies, and assay kits. Our products are developed under rigorous quality control systems and are intended for basic research use only. We believe that reliable reagents accelerate discovery, and we continuously invest in platform development to support the global research community.

Disclaimer

This article was created with partial assistance from artificial intelligence. If any content involves copyright or intellectual property issues, please notify us, and we will verify and remove it promptly. The information provided is for basic research reference only and does not constitute clinical or diagnostic guidance.